«Previous Article|Table of Contents|Next Article»

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:

2025 01

Page:

26-31

Research Field:

Publishing date:

Info

Title:

MiRNA-6507 enhances cisplatin sensitivity in cervical cancer cells and its mechanism exploration

Author(s):

ZHANG Haiguang¹; ZHAO Jingjing²; ZHANG Min²; CUI Feifei²; WANG Zhaohui²; YANG Jun¹; WANG Guoqiang²

1.Department of Gynecology and Obstetrics;2.Clinical Lab,the First Affiliated Hospital of Xinxiang Medical University,Henan Xinxiang 453100,China.

Keywords:

cervical carcinoma; 5-year survival rate; cisplatin sensitivity; miRNA

PACS:

R737.33

DOI:

10.3969/j.issn.1672-4992.2025.01.005

Abstract:

Objective:Exploring the effect and mechanism of miRNA-6507 on cisplatin sensitivity in cervical cancer cells.Methods:The miRNA and clinical data related to cervical cancer were downloaded from the TCGA database to analyze the miRNA expression differences between adjacent and cancerous tissues,the miRNA related to patient survival was further analysis.The expression difference of miRNA between normal cervical cells and cervical carcinoma cells was verified by RT-qPCR.The miRNA related to the 5-year survival rate of patients was chosen,and the miRNA mimics and controls were transfected into cervical cancer cell lines.MTT was used to detect cell viability,and cell sensitivity to cisplatin was detected after cisplatin was added to transfected cells.Results:There were 256 tumor tissues and 2 para-cancer tissues in TCGA database.edgeR analysis showed that among 1 881 miRNA associated with cervical cancer,19 were up-regulated and 70 were down-regulated in tumor tissues compared with adjacent tissues.Each of the 89 miRNA were divided into high expression group and low expression group for survival analysis,results showed that miRNA-140,miRNA-145,miRNA-200c,and miRNA-6507 were correlated with the survival of patients.The high expression of miRNA-140,miRNA-145 and miRNA-6507 can improve the survival of patients,and the high expression of miRNA-200c can reduce the survival of patients.RT-qPCR results showed that the expression of miRNA-140 in cervical cancer cell lines Caski,HCC94 and Siha was significantly higher than that in cervical cancer cells H8,but there was no significant difference in C33A and Hela cells.The expression of miRNA-145 was decreased in all cervical cancer cells,which was consistent with survival analysis.The expression of miRNA-200c was up-regulated in Caski and HCC94 cervical cancer cells,which was the same as the results of survival analysis,but there was no significant change in the expression of miRNA-200c in C33A,Hela and Siha cells.The expression level of miRNA-6507 in the five cervical cancer cells verified was lower than that of normal cell line H8,which was consistent with survival analysis.MTT results showed that the cell viability of C33A and Siha after miRNA-6507 mimics transfection was not affected,and the cell viability of miRNA-6507 transfected cells after cisplatin treatment was decreased.Conclusion:miRNA-6507 can enhance the cisplatin sensitivity of cervical cancer cells and may be a candidate miRNA for cervical cancer treatment.

References:

£Û1£Ý BOON SS,LUK HY,XIAO C,et al.Review of the standard and advanced screening,staging systems and treatment modalities for cervical cancer£ÛJ£Ý.Cancers(Basel),2022,14(12):2913.
£Û2£Ý REN X,WU W,LI Q,et al.Advances in research,diagnosis,and treatment of neuroendocrine cervical carcinoma:A review£ÛJ£Ý.Oncology Reviews,2023,17:11764.
£Û3£Ý VOLKOVA LV,PASHOV AI,OMELCHUK NN.Cervical carcinoma:Oncobiology and biomarkers£ÛJ£Ý.Int J Mol Sci,2021,22(22):12571.
£Û4£Ý DUENAS-GONZALEZ A.Combinational therapies for the treatment of advanced cervical cancer£ÛJ£Ý.Expert Opin Pharmacother,2023,24(1):73-81.
£Û5£Ý BRAY F,LAVERSANNE M,SUNG H,et al.Global cancer statistics 2022:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries£ÛJ£Ý.CA:A Cancer Journal for Clinicians,2024,74(3):229-263.
£Û6£Ý LI X,ZHENG R,LI X,et al.Trends of incidence rate and age at diagnosis for cervical cancer in China,from 2000 to 2014£ÛJ£Ý.Chin J Cancer Res,2017,29(6):477-486.
£Û7£Ý LOGAN M,HAWKINS SM.Role of microRNAs in cancers of the female reproductive tract:insights from recent clinical and experimental discovery studies£ÛJ£Ý.Clin Sci (Lond),2015,128(3):153-180.
£Û8£Ý ALLEGRA A,MUSOLINO C,TONACCI A,et al.Interactions between the microRNAs and microbiota in cancer development:Roles and therapeutic opportunities£ÛJ£Ý.Cancers(Basel),2020,12(4):805.
£Û9£Ý PEDROZA-TORRES A,L¦VPEZ-URRUTIA E,GARC¦PA-CASTILLO V,et al.microRNAs in cervical cancer:evidences for a miRNA profile deregulated by HPV and its impact on radio-resistance£ÛJ£Ý.Molecules,2014,19(5):6263-6281.
£Û10£Ý JIANG Q,YUE S,YU K,et al.Endogenous microRNA triggered enzyme-free DNA logic self-assembly for amplified bioimaging and enhanced gene therapy via in situ generation of siRNAs£ÛJ£Ý.J Nanobiotechnology,2021,19(1):288.
£Û11£Ý SUN Z,NIU S,XU F,et al.circAMOTL1 promotes tumorigenesis through miR-526b/SIK2 Axis in cervical cancer£ÛJ£Ý.Front Cell Dev Biol,2020,8:568190.
£Û12£Ý OCADIZ-DELGADO R,CRUZ-COLIN JL,ALVAREZ-RIOS E,et al.Expression of miR-34a and miR-15b during the progression of cervical cancer in a murine model expressing the HPV16 E7 oncoprotein£ÛJ£Ý.J Physiol Biochem,2021,77(4):547-555.
£Û13£Ý YU DS,SONG XL,YAN C.Oncogenic miRNA-1908 targets HDAC10 and promotes the aggressive phenotype of cervical cancer cell£ÛJ£Ý.Kaohsiung J Med Sci,2021,37(5):402-410.
£Û14£Ý CHAO-HUI H,JING L,XUE C,et al.Relationship between expression of microRNA and chemotherapy resistance in cervical carcinoma£ÛJ£Ý.Appl Biochem Biotechnol,2023,195(3):1928-1946.
£Û15£Ý ½ªÎÄ¿­£¬ÖÜÎIJߣ¬Àîê¿.ÍâÃÚÌåmiRNAÓëÒÈÏÙ°©¹ØϵµÄÑо¿½øÕ¹£ÛJ£Ý.ÏÖ´úÖ×Áöҽѧ£¬2021£¬29(07):1267-1270. JIANG Wenkai,ZHOU Wence,LI Xin.Advances in the relationship of exosomal miRNA for pancreatic cancer£ÛJ£Ý.Modern Oncology,2021,29(07):1267-1270.
£Û16£Ý Ê·ÐÓµ¤£¬Îâèª.miRNAÔÚ¶ñÐÔºÚÉ«ËØÁöÖеIJîÒìÐÔ±í´ï¼°ÁÙ´²ÒâÒå£ÛJ£Ý.ÏÖ´úÖ×Áöҽѧ£¬2020,28(24):4375-4378. SHI Xingdan,WU Jin.Differential expression and clinical significance of miRNA in malignant melanoma£ÛJ£Ý.Modern Oncology,2020,28(24):4375-4378.
£Û17£Ý µËÓÜÞ±£¬Â·µ¤.miRNAsÔÚÈýÒõÐÔÈéÏÙ°©¶àÒ©ÄÍÒ©ÐÔÖеÄÑо¿½øÕ¹£ÛJ£Ý.ÏÖ´úÖ×Áöҽѧ£¬2019,27(23):4304-4307. DENG Yuwei,LU Dan.Research progress of miRNAs in multidrug resistance of triple negative breast cancer£ÛJ£Ý.Modern Oncology,2019,27(23):4304-4307.
£Û18£Ý ZHANG H,CAI S,XIA Y,et al.Association between human herpesvirus infection and cervical carcinoma:a systematic review and meta-analysis£ÛJ£Ý.Virology Journal,2023,20(1):1-28.
£Û19£Ý PI¦rA-S¦BNCHEZ P.Human papillomavirus:Challenges and opportunities for the control of cervical cancer£ÛJ£Ý.Arch Med Res,2022,53(8):753-769.
£Û20£Ý CHU D,LIU T,YAO Y.Implications of viral infections and oncogenesis in uterine cervical carcinoma etiology and pathogenesis£ÛJ£Ý.Front Microbiol,2023,14:1194431.
£Û21£Ý ZHAO W,LIU Y,ZHANG L,et al.microRNA-154-5p regulates the HPV16 E7-pRb pathway in cervical carcinogenesis by targeting CUL2£ÛJ£Ý.Journal of Cancer,2020,11(18):5379-5389.
£Û22£Ý CAO L,JIN H,ZHENG Y,et al.DANCR-mediated microRNA-665 regulates proliferation and metastasis of cervical cancer through theERK/SMAD pathway£ÛJ£Ý.Cancer Science,2019,110(3):913-925.
£Û23£Ý LIU X,ZHOU Y,NING Y,et al.miR-195-5p inhibits malignant progression of cervical cancer by targeting YAP1£ÛJ£Ý.Onco Targets and Therapy,2020,13:931-944.
£Û24£Ý NI M,YAN Q,XUE H,et al.Identification of MYLIP gene and miRNA-802 involved in the growth and metastasis of cervical cancer cells£ÛJ£Ý.Cancer Biomarkers,2021,30(3):287-298.
£Û25£Ý FAN Y,SHENG W,MENG Y,et al.LncRNA PTENP1 inhibits cervical cancer progression by suppressing miR-106b£ÛJ£Ý.Artif Cells Nanomed Biotechnol,2020,48(1):393-407.
£Û26£Ý CHEN S,GAO C,WU Y,et al.Identification of prognostic miRNA signature and lymph node metastasis-related key genes in cervical cancer£ÛJ£Ý.Frontiers in Pharmacology,2020,11:544.
£Û27£Ý TEWARI KS,COLOMBO N,MONK BJ,et al.Pembrolizumab or placebo plus chemotherapy with or without bevacizumab for persistent,recurrent,or metastatic cervical cancer£ÛJ£Ý.JAMA Oncology,2023,10(2):185-192.

Memo

Memo:

ÐÂÏçҽѧԺµÚÒ»¸½ÊôÒ½ÔºÇàÄê¿Æѧ»ù½ð£¨±àºÅ£ºQN-2021-A05£¬QN-2021-B14£©

Common functions

Last Update: 1900-01-01